NCT01780428View on ClinicalTrials.gov

Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

December 31, 2014

Conditions
PainNauseaVomiting
Interventions
DRUG

CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)

DRUG

Placebo

Trial Locations (1)

19104-6030

University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
lead

Charleston Laboratories, Inc

INDUSTRY

NCT01780428 - Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain | Biotech Hunter | Biotech Hunter